Chinese innovative drugs continue to demonstrate R&D strength and molecular originality at aacr 2026

Overview

This report looks ahead to aacr 2026 and assesses the participation and R&D quality of Chinese biotech and pharmaceutical companies in global oncology innovation. The report notes that aacr 2026 will be held in San Diego from April 17 to April 22, 2026, with regular abstracts released on April 3 and late-breaking and clinical-trial abstracts to be released during the conference. Initial abstract titles suggest that Chinese participation continues to increase, while showing stronger originality in adc, bispecifics/multispecifics, trispecifics, first-in-class, and less crowded target areas.

Core views

The core view is that China's innovative drug industry is continuing to move up the innovation curve. China-origin abstracts account for about 9% of the global total, up roughly 1 percentage point from aacr 2025's 8%; more than 140 Chinese companies are expected to present over 250 drug assets. Although the conference data are generally still at the preclinical or early clinical stage, they are important for investors to judge molecular originality, differentiation, and the next stage of R&D trends.

Analysis framework

The report mainly uses abstract counts, company participation, the number of drug assets, target distribution, technology platforms, and a list of key clinical data readouts to judge the competitive position of Chinese innovative drug companies in global oncology R&D. The focus is not short-term financial forecasts, but pipeline quality, target crowding, molecular-mechanism differentiation, and potential BD value.

Methodology notes

• Conference abstract previewAACR abstract and clinical data readout tracking

  Track company R&D directions through AACR abstract titles, regular abstracts, and late-breaking/clinical-trial abstracts.

  This approach is suitable for identifying early R&D trends and molecular innovation directions, but because most data are still at the preclinical or early clinical stage, it cannot be directly equated with commercial success.

• R&D pipeline assessmentTarget and technology platform mapping

  Observe differentiation across pd-1/pd-l1, cldn18.2, kras g12c, egfr, b7-h3, pd-1 x vegf, adc, bispecifics/multispecifics, and similar dimensions.

  The report uses target popularity, mechanistic novelty, and platform technology to judge whether Chinese companies are shifting from fast followers to original R&D.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Hengrui HRS-6209

  Key clinical program

  Strengths

  As a cdk4 program, it is intended to address resistance to existing cdk4/6 inhibitors and toxicity limitations.

  Weaknesses

  Clinical data are still needed to prove differentiation and safety advantages.

  Comparison

  Will be compared with the existing cdk4/6 treatment framework in terms of mechanism and tolerability.

  Risks

  If efficacy or toxicity improvement is not obvious, differentiation value may be limited.

• Hansoh HS-10504

  Key clinical program

  Strengths

  A fourth-generation egfr tki targeting the egfr c797s mutation that causes resistance to third-generation tki.

  Weaknesses

  The eligible patient population and real-world clinical benefit still need validation.

  Comparison

  Mainly compared with treatment options after resistance to third-generation egfr tki.

  Risks

  Resistance mechanisms are complex, and coverage of a single mutation may not be sufficient.

• Hansoh HS-20093

  Key clinical program

  Strengths

  The b7-h3 adc is a high-priority program for the company and may disclose combination data with pd-l1 in second-line non-squamous nsclc.

  Weaknesses

  adc efficacy, safety window, and combination-tolerability still need data confirmation.

  Comparison

  Needs to compete with other b7-h3 adc and oncology adc platforms.

  Risks

  If the toxicity or efficacy of combination therapy falls short of expectations, program priority may be affected.

• CSPC SYS6010

  Key clinical program

  Strengths

  An egfr adc that previously drew market bd expectations and will report data in nasopharyngeal carcinoma.

  Weaknesses

  Commercial partnership value depends on data differentiation and indication potential.

  Comparison

  Will be compared with other egfr adc and existing nasopharyngeal carcinoma treatment regimens.

  Risks

  If the data do not show a clear advantage, bd expectations may cool.

• Merck MK-2010 / LaNova

  Chinese biotech licensed asset

  Strengths

  Licensed by the Chinese biotech company LaNova to Merck, highlighting the potential for global collaboration in Chinese pipelines.

  Weaknesses

  Phase 1 data are still in the early validation stage.

  Comparison

  Will be compared with other pd-1 x vegf competitors.

  Risks

  Competition among similar mechanisms is intense, and early data uncertainty is high.

• Junshi JS212 / JS207

  Key clinical program

  Strengths

  EGFR/HER3 adc and pd-1/vegf bispecific antibody, respectively, with combination exploration in crc and hcc.

  Weaknesses

  Combination regimens are complex and require a high balance between efficacy and safety.

  Comparison

  Competes with other assets in the adc and pd-1/vegf bispecific spaces.

  Risks

  Indication competition is intense, and data timing and patient selection will affect interpretation.

• Akeso AK104 plus chemo

  Key clinical program

  Strengths

  Phase 2 data in first-line hcc will help assess the potential of bispecific plus chemotherapy.

  Weaknesses

  More mature data are needed to support further development.

  Comparison

  Competes with other first-line immunotherapy combinations in hcc.

  Risks

  If the incremental efficacy is limited or toxicity is high, the value of clinical advancement will be affected.

• Everest EVM16

  Key clinical program

  Strengths

  The personalized mrna vaccine disclosed first-in-human data in advanced/recurrent solid tumors, including monotherapy and pd-1 combination cohorts.

  Weaknesses

  Personalized vaccines are relatively complex to commercialize and manufacture.

  Comparison

  Compared with other cancer vaccines and immunotherapy combination therapies.

  Risks

  Early sample sizes are limited, and the translation from immune response to clinical benefit remains uncertain.

Key data

• aacr 2026 meeting dates2026-04-17 to 2026-04-22The conference will be held in San Diego, United States.
• China-origin abstract count800+About 9% of the global total of 9,500+ abstracts.
• YoY change in China's share of global abstractsabout +1 percentage pointChina-origin abstracts accounted for about 8% at aacr 2025.
• Expected number of Chinese companies attending and presenting140+Covers Chinese biotech and pharmaceutical companies.
• Expected number of drug assets presented250+ADC, bispecifics/multispecifics, trispecifics, and early-stage innovative pipelines are important components.

Impact & implications

For investors, aacr 2026 provides an early signal for observing the R&D direction and potential BD value of Chinese innovative drug companies. If Chinese companies show stronger molecular originality, combination-therapy potential, and platform scalability in early data, market attention may intensify around global licensing, best-in-class competition, and first-in-class breakthroughs in Chinese innovative drugs; however, preclinical and early clinical results still need follow-up validation of efficacy, safety, and commercialization.

Risks

• Most aacr-related data are still at the preclinical or early clinical stage, and there is significant uncertainty in extrapolating them to late-stage success and commercialization.
• Hot targets such as pd-1/pd-l1, cldn18.2, kras g12c, adc, and bispecifics are crowded, and insufficient differentiation may weaken investment value.
• Combination therapies and complex biotech platforms may bring higher safety, manufacturing, clinical design, and regulatory risks.
• Abstract titles and early disclosures are limited, and the judgment on program quality may change after full data release.

What to watch

• Late-breaking and clinical-trial abstracts released on April 17.
• Data from programs such as Hengrui HRS-6209, Hansoh HS-10504, HS-20093, CSPC SYS6010, Merck MK-2010, Junshi JS212/JS207, Akeso AK104 plus chemotherapy, and Everest EVM16.
• Evidence of originality among Chinese companies in adc, bispecifics/multispecifics, trispecifics, dual-target adc, and AI-assisted target discovery.
• first-in-class or less crowded target directions, including pdia6-ire1, 5t4, egfr/cmet, cd3/cldn18.2/cdh17, sstr2xdll3, cbl-b, nkg2a, lgr5, il1rap, cdh6, wrn, gpc3, cldn6, kif18a, and polq.